Jefford Michael, Gough Karla, Drosdowsky Allison, Russell Lahiru, Aranda Sanchia, Butow Phyllis, Phipps-Nelson Jo, Young Jane, Krishnasamy Mei, Ugalde Anna, King Dorothy, Strickland Andrew, Franco Michael, Blum Robert, Johnson Catherine, Ganju Vinod, Shapiro Jeremy, Chong Geoffrey, Charlton Julie, Haydon Andrew, Schofield Penelope
Department of Cancer Experiences Research, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia
Department of Cancer Experiences Research, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.
Oncologist. 2016 Aug;21(8):1014-23. doi: 10.1634/theoncologist.2015-0533. Epub 2016 Jun 15.
Colorectal cancer (CRC) and its treatments can cause distressing sequelae. We conducted a multicenter randomized controlled trial aiming to improve psychological distress, supportive care needs (SCNs), and quality of life (QOL) of patients with CRC. The intervention, called SurvivorCare (SC), comprised educational materials, needs assessment, survivorship care plan, end-of-treatment session, and three follow-up telephone calls.
At the end of treatment for stage I-III CRC, eligible patients were randomized 1:1 to usual care (UC) or to UC plus SC. Distress (Brief Symptom Inventory 18), SCNs (Cancer Survivors' Unmet Needs measure), and QOL (European Organization for Research and Treatment of Cancer [EORTC] QOL questionnaires C30 and EORTC CRC module CR29) were assessed at baseline and at 2 and 6 months (follow-up 1 [FU1] and FU2, respectively). The primary hypothesis was that SC would have a beneficial effect on distress at FU1. The secondary hypotheses were that SC would have a beneficial effect on (a) SCN and QOL at FU1 and on (b) distress, SCNs, and QOL at FU2. A total of 15 items assessed experience of care.
Of 221 patients randomly assigned, 4 were ineligible for the study and 1 was lost to FU, leaving 110 in the UC group and 106 in the SC group. Patients' characteristics included the following: median age, 64 years; men, 52%; colon cancer, 56%; rectal cancer, 35%; overlapping sites of disease, 10%; stage I disease, 7%; stage II, 22%; stage III, 71%. Baseline distress and QOL scores were similar to population norms. Between-group differences in distress at FU1 (primary outcome) and at FU2, and SCNs and QOL at FU1 and FU2 were small and nonsignificant. Patients in the SC group were more satisfied with survivorship care than those in the UC group (significant differences on 10 of 15 items).
The addition of SC to UC did not have a beneficial effect on distress, SCNs, or QOL outcomes, but patients in the SC group were more satisfied with care.
Some survivors of colorectal cancer report distressing effects after completing treatment. Strategies to identify and respond to survivors' issues are needed. In a randomized controlled trial, the addition of a nurse-led supportive care package (SurvivorCare) to usual post-treatment care did not impact survivors' distress, quality of life, or unmet needs. However, patients receiving the SurvivorCare intervention were more satisfied with survivorship care. Factors for consideration in the design of subsequent studies are discussed.
结直肠癌(CRC)及其治疗可能会导致令人痛苦的后遗症。我们开展了一项多中心随机对照试验,旨在改善CRC患者的心理困扰、支持性护理需求(SCNs)和生活质量(QOL)。名为“幸存者护理(SC)”的干预措施包括教育材料、需求评估、生存护理计划、治疗结束环节以及三次随访电话。
在I - III期CRC治疗结束时,符合条件的患者按1:1随机分为常规护理(UC)组或UC加SC组。在基线以及2个月和6个月时(分别为随访1 [FU1]和随访2 [FU2])评估困扰程度(简明症状量表18)、SCNs(癌症幸存者未满足需求测量量表)和QOL(欧洲癌症研究与治疗组织[EORTC] QOL问卷C30和EORTC CRC模块CR29)。主要假设是SC在FU1时对困扰程度有有益影响。次要假设是SC在(a)FU1时对SCN和QOL以及(b)FU2时对困扰程度、SCNs和QOL有有益影响。总共15个项目评估了护理体验。
在221名随机分组的患者中,4名不符合研究条件,1名失访,UC组剩下110名患者,SC组剩下106名患者。患者特征如下:年龄中位数为64岁;男性占52%;结肠癌占56%;直肠癌占35%;疾病重叠部位占10%;I期疾病占7%;II期占22%;III期占71%。基线时的困扰程度和QOL评分与总体标准相似。FU1(主要结局)和FU2时两组之间在困扰程度、FU1和FU2时的SCNs和QOL方面的差异较小且无统计学意义。SC组患者对生存护理的满意度高于UC组患者(15个项目中有10个项目存在显著差异)。
在UC基础上加用SC对困扰程度、SCNs或QOL结局没有有益影响,但SC组患者对护理的满意度更高。
一些结直肠癌幸存者在完成治疗后报告有令人痛苦的影响。需要有识别和应对幸存者问题的策略。在一项随机对照试验中,在常规治疗后护理基础上加用由护士主导的支持性护理包(幸存者护理)并未影响幸存者的困扰程度、生活质量或未满足的需求。然而,接受幸存者护理干预的患者对生存护理更满意。讨论了后续研究设计中需考虑的因素。